Administrative data and scientific evidence: a lesson from France – the safety of systemic treatment for psoriasis during the COVID‐19 pandemic

Linked Article: Penso et al. Br J Dermatol 2022; 186:59–68.

Saved in:
Bibliographic Details
Published inBritish Journal of Dermatology Vol. 186; no. 1; pp. 7 - 8
Main Authors Cazzaniga, S., Naldi, L.
Format Journal Article Web Resource
LanguageEnglish
Published England John Wiley & Sons, Inc 01.01.2022
Oxford University Press
John Wiley and Sons Inc
Subjects
Commentaries
COVID-19
France - epidemiology
Humans
Pandemics
Psoriasis
Psoriasis - drug therapy
Psoriasis - epidemiology
SARS-CoV-2
France
Online AccessGet full text

Cover

More Information
Summary:Linked Article: Penso et al. Br J Dermatol 2022; 186:59–68.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Commentary-3
content type line 23
Conflicts of interest: L.N. has been a consultant for AbbVie, Almirall, Bristol Myers Squibb, Janssen, Leo, Novartis and Sanofi. S.C. has no conflicts of interest to declare.
ISSN:0007-0963
1365-2133
DOI:10.1111/bjd.20776